A Phase 1b Open Label Clinical Trial to Evaluate HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs HIV gp120 vaccine (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacodynamics
- 18 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Jan 2019 Status changed from not yet recruiting to recruiting.
- 10 Dec 2018 Planned End Date changed from 15 Apr 2020 to 15 Sep 2020.